(Adds portfolio manager comment, updates prices to close)
* TSX ends down 36.82 points, or 0.25 percent, at 14,689.04
* Seven of the TSX's 10 main groups move lower
By Alastair Sharp
TORONTO, Oct 3 Canada's main stock index fell on
Monday, as major gold miners lost ground and heavyweight banks
also pulled back as the federal government tightened mortgage
and tax rules in a bid to cool the housing market.
The most influential stocks weighing on the index included
Goldcorp Inc which fell 4.5 percent to C$20.68 after it
temporarily shut down its Peñasquito gold mine in Mexico due to
a week-long blockade by a trucking contractor.
Barrick Gold Corp, which is dealing with its own
forced shutdown of operations at a mine in Argentina, lost 1.9
percent to C$22.78.
The materials group, which includes precious and base metals
miners and fertilizer companies, lost 1.8 percent.
"Apart from the trials and tribulations of the giant gold
companies which are mostly Canadian, the mining companies are
experiencing a growing arrival of free cash flows," said Michael
Smedley, chief portfolio manager at Morgan Meighen & Associates.
The Toronto Stock Exchange's S&P/TSX composite index
closed down 36.82 points, or 0.25 percent, at
Seven of the index's 10 main groups ended in negative
The financials group slipped 0.2 percent, as Ottawa said it
will close a tax loophole and introduce a stress test to insured
Investors were also more cautious as Britain set a March
deadline to start its withdrawal from the European Union and
worries over Deutsche Bank continued to swirl.
Royal Bank of Canada fell 0.4 percent to C$80.95 and
Canadian Imperial Bank of Commerce lost 0.7 percent to
Shares in fashion retailer Aritzia Inc settled at
C$17.71 in their market debut, after they were priced at C$16
The energy sector gained 0.6 percent as Brent settled above
$50 a barrel for the first time since August and U.S. crude hit
three-month highs, after Iran exhorted the need for other oil
producers to join OPEC in supporting the market.
Shares in Spectral Medical Inc slumped 85 percent
to 24 Canadian cents after it said its experimental treatment
for sepsis - a common, often deadly complication of infection -
failed a late-stage study, stymieing the company's plans to
bring to market the first U.S. Food and Drug
Administration-approved device for the condition.
(Reporting by Alastair Sharp; Editing by Jonathan Oatis and